- Home
- HOWL vs CVM Comparison
HOWL vs CVM Comparison
Compare HOWL & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOWL | CVM |
|---|---|---|
| Founded | 2017 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 32.4M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HOWL | CVM |
|---|---|---|
| Price | $0.81 | $3.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 301.7K | 57.1K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.53 | $0.23 |
| 52 Week High | $2.23 | $13.48 |
Technical Indicators
Market Signals| Indicator | HOWL | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 37.82 |
| Support Level | $0.80 | $3.18 |
| Resistance Level | $0.90 | $4.84 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 3.35 | 2.50 |
Price Performance
Historical ComparisonAbout HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.